Deep knowledge on 
 small-molecule drugs and 
 the 100,000 global patents 
 covering them 

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 5,702,725

« Back to Dashboard
Patent 5,702,725 protects EXALGO and is included in one NDA.

This patent has fourteen patent family members in eleven countries.

Summary for Patent: 5,702,725

Title: Hydromorphone therapy
Abstract:A hydromorphone composition, a hydromorphone dosage form and a method for administering hydromorphone are disclosed, indicated for the management of pain.
Inventor(s): Merrill; Sonya (San Jose, CA), Ayer; Atul Devdatt (Palo Alto, CA), Chadha; Navjot (Sunnyvale, CA), Kuczynski; Anthony L. (Mt. View, CA)
Assignee: Alza Corporation (Palo Alto, CA)
Application Number:08/611,294
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use; Delivery;
Patent Metrics:
Source: PatentStat.com
Field: Not categorized
Back Citations: 17
Forward Citations: 3
Patent PDF download available with subscription

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Mallinckrodt Inc
EXALGO
hydromorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL021217-001Mar 1, 2010RXNo5,702,725<disabled>Y MANAGEMENT OF MODERATE TO SEVERE PAIN
Mallinckrodt Inc
EXALGO
hydromorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL021217-002Mar 1, 2010RXNo5,702,725<disabled>Y MANAGEMENT OF MODERATE TO SEVERE PAIN
Mallinckrodt Inc
EXALGO
hydromorphone hydrochloride
TABLET, EXTENDED RELEASE;ORAL021217-003Mar 1, 2010RXNo5,702,725<disabled>Y MANAGEMENT OF MODERATE TO SEVERE PAIN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,702,725

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,529,787 Hydromorphone therapy<disabled in preview>
5,914,131 Hydromorphone therapy<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,702,725

Country Document Number Publication Date Supplementary Protection Certificate SPC Country SPC Expiration
Spain2186302May 01, 2003
South Africa9505674Feb 20, 1996
Austria227575Nov 15, 2002
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc